Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Dyne Therapeutics Inc (NASDAQ: DYN) was $11.88 for the day, down -3.88% from the previous closing price of $12.36. In other words, the price has decreased by -$3.88 from its previous closing price. On the day, 1.33 million shares were traded. DYN stock price reached its highest trading level at $12.63 during the session, while it also had its lowest trading level at $11.825.
Ratios:
Our analysis of DYN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 15.60 and its Current Ratio is at 15.60. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BMO Capital Markets on March 12, 2025, initiated with a Outperform rating and assigned the stock a target price of $50.
On March 07, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $50.
On December 13, 2024, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $46.Robert W. Baird initiated its Outperform rating on December 13, 2024, with a $46 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 13 ’25 when Friedl-Naderer Johanna sold 143 shares for $12.12 per share. The transaction valued at 1,733 led to the insider holds 96,057 shares of the business.
Scalzo Richard William sold 1,343 shares of DYN for $15,283 on Mar 11 ’25. The SVP, Head of Finance & Admin. now owns 122,330 shares after completing the transaction at $11.38 per share. On Mar 11 ’25, another insider, Beskrovnaya Oxana, who serves as the Chief Scientific Officer of the company, sold 2,153 shares for $11.38 each. As a result, the insider received 24,501 and left with 195,840 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DYN now has a Market Capitalization of 1343877504 and an Enterprise Value of 725601728.
Stock Price History:
The Beta on a monthly basis for DYN is 1.13, which has changed by -0.5755627 over the last 52 weeks, in comparison to a change of 0.07903516 over the same period for the S&P500. Over the past 52 weeks, DYN has reached a high of $47.45, while it has fallen to a 52-week low of $11.18. The 50-Day Moving Average of the stock is -22.16%, while the 200-Day Moving Average is calculated to be -60.00%.
Shares Statistics:
DYN traded an average of 1.94M shares per day over the past three months and 1792460 shares per day over the past ten days. A total of 102.32M shares are outstanding, with a floating share count of 84.03M. Insiders hold about 25.71% of the company’s shares, while institutions hold 81.00% stake in the company. Shares short for DYN as of 1740700800 were 11667343 with a Short Ratio of 6.01, compared to 1738281600 on 9558513. Therefore, it implies a Short% of Shares Outstanding of 11667343 and a Short% of Float of 12.020000999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The performance of Dyne Therapeutics Inc (DYN) in the stock market is under the watchful eye of 9.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.85, with high estimates of -$0.66 and low estimates of -$1.06.
Analysts are recommending an EPS of between -$2.78 and -$4.37 for the fiscal current year, implying an average EPS of -$3.46. EPS for the following year is -$3.67, with 9.0 analysts recommending between -$3.0 and -$4.85.
